» Articles » PMID: 28861888

Effect of Qingfei Mixture () on Pediatric Mycoplasma Pneumoniae Pneumonia with Phlegm Heat Obstructing Fei (Lung) Syndrome

Overview
Date 2017 Sep 2
PMID 28861888
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the effect and mechanism of Qingfei Mixture (), a Chinese medicine, in treating mycoplasma pneumonia (MP) in MP patients and rat model METHODS: A total of 46 MP children with phlegm heat obstructing Fei (Lung) syndrome were randomly assigned to two groups by the method of random number table, with 23 children in each group. The control group was treated with intravenous infusion of azithromycin; the treatment group received intravenous infusion of azithromycin and oral administration of Qingfei Mixture. The treatment course was 7 days. Major symptoms and minor symptoms were observed and scored before and after treatments. A rat model of MP was also established. A total of 120 wistar rats were randomly divided into 5 groups: a normal group, infection group, Qingfei Mixture treatment group, azithromycin treatment group, and Qingfei Mixture + azithromycin treatment group. Each group contained 24 rats, from which every 6 were euthanatized 1, 3, 7 and 14 days after infection. MP DNA in pulmonary tissue homogenates was detected using real-time fluorescence quantitative polymerase chain reaction. Pathology was assessed after hematoxylin (HE) staining and lung tissue pathology scores were determined in pulmonary tissue. Transmission electron microscopic detection and electronic image analysis were performed on lung tissue 3 days after infection. Interleukin (IL)-17 was detected in serum using enzymelinked immunosorbent assay (ELISA) 7 days after infection.

Results: In the clinical study, both control and the treatment group showed improved results on removing symptoms of phlegm heat syndrome compared to the control group (P<0.05). In animal experiments, On the 7th day after MP infection, as detected by electron microscopy, the pulmonary capillary basement membranes of the azithromycin + Qingfei Mixture treatment group were much thinner than those of the azithromycin or Qingfei mixture treatment groups (P<0.05). The level of serum IL-17 in the azithromycin + Qingfei Mixture treatment group was lower than that in the azithromycin or Qingfei Mixture groups (P<0.01).

Conclusion: Both Qingfei Mixture and azithromycin have therapeutic effects on mycoplasma pneumoniae pneumonia, but the combination of both agents had the greatest effect.

Citing Articles

Wuhu decoction combined with azithromycin for treatment of pneumoniae pneumonia in Asian children: a systematic review and meta analysis of randomized controlled trials.

Yang S, Liu X, Wang H, Wang H, Sun D, Han Y Front Pharmacol. 2024; 15:1329516.

PMID: 38633618 PMC: 11021718. DOI: 10.3389/fphar.2024.1329516.


Shuanghuanglian oral preparations combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: A systematic review and meta-analysis of randomized controlled trials.

Peng Y, Chen Z, Li Y, Lu Q, Li H, Han Y PLoS One. 2021; 16(7):e0254405.

PMID: 34255785 PMC: 8277054. DOI: 10.1371/journal.pone.0254405.


Traditional Chinese Medicine Oral Liquids Combined With Azithromycin for Pneumonia in Children: A Bayesian Network Meta-Analysis.

Chen Z, Shi Q, Peng Y, Chen Y, Cao L, Pang B Front Pharmacol. 2021; 12:652412.

PMID: 34122075 PMC: 8194818. DOI: 10.3389/fphar.2021.652412.


Ameliorative Effects of Infantile Feire Kechuan Oral Solution on Mycoplasma Pneumoniae Pneumonia in Infant Mouse and Rat Models.

Guo S, Bao L, Qu T, Mao X, Gao Y, Xu Y Evid Based Complement Alternat Med. 2018; 2018:8139040.

PMID: 30305831 PMC: 6166364. DOI: 10.1155/2018/8139040.

References
1.
Du J, Han J, Zhang Y, Qi G, Li H, Zhang Y . Single-Nucleotide Polymorphisms of IL-17 Gene Are Associated with Asthma Susceptibility in an Asian Population. Med Sci Monit. 2016; 22:780-7. PMC: 4793684. DOI: 10.12659/msm.895494. View

2.
Kannan T, Musatovova O, Balasubramanian S, Cagle M, Jordan J, Krunkosky T . Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection-dependent regulation. Mol Microbiol. 2010; 76(5):1127-41. PMC: 2883071. DOI: 10.1111/j.1365-2958.2010.07092.x. View

3.
Wan Y, Huang Z, Jing K, Li J, Wang Y, Xu C . Azithromycin attenuates pulmonary inflammation and emphysema in smoking-induced COPD model in rats. Respir Care. 2014; 60(1):128-34. DOI: 10.4187/respcare.03344. View

4.
Yan T . Role of anti-inflammatory cytokines in pathogenesis of pediatric mycoplasma pneumoniae pneumonia. J Biol Regul Homeost Agents. 2016; 30(2):541-5. View

5.
Kannan T, Coalson J, Cagle M, Musatovova O, Hardy R, Baseman J . Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model. J Infect Dis. 2011; 204(10):1596-604. PMC: 3222103. DOI: 10.1093/infdis/jir557. View